IL2 and cancer: The fact that IL‐2 treatment has been approved by the United States Food and Drug Administration for cancer immunotherapy and is currently being tested in clinical trials for the treatment of chronic viral infections further supports our recommendation of LGG therapy for patients undergoing HMV treatment.